Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00365105 · ClinicalTrials.gov registry record · Phase 3
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
A Phase 3 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 261
- Enrollment target
NCT00365105 is a Phase 3 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 261 participants.
The verdict
NCT00365105, a Phase 3 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 261 participants
- Enrollment target
Study Summary
RATIONALE: Zoledronate, vitamin D and calcium may prevent or delay bone pain and other symptoms caused by bone metastases. It is not yet known whether giving zoledronate together with vitamin D and calcium is more effective with or without strontium 89 or samarium 153 in treating patients with bone metastases from prostate cancer, lung cancer, or breast cancer. PURPOSE: This randomized phase III trial is studying zoledronate, vitamin D, and calcium to see how well they work compared to zoledronate, vitamin D, calcium, and either strontium 89 or samarium 153 in preventing or delaying bone problems in patients with bone metastases from prostate cancer, lung cancer, or breast cancer.
Interventions
- DIETARY_SUPPLEMENT Vitamin D
- DRUG zoledronic acid
- DIETARY_SUPPLEMENT Calcium
- DRUG Sm-153
- RADIATION Sr-89
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 261 participants |
| Start Date | 2006-07-11 |
| Est. Completion | 2017-02-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00365105
The ClinicalTrials.gov registry entry for NCT00365105 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 261 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Vitamin D is the first listed.
NCT00365105 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00365105 about?
NCT00365105 is a clinical study titled "Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer". RATIONALE: Zoledronate, vitamin D and calcium may prevent or delay bone pain and other symptoms caused by bone metastases. It is not yet known whether giving zoledronate together with vitamin D and calcium is more effective with or without strontium 89 or samarium 153 in treating patients with bone ...
What is the current status of trial NCT00365105?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 261 participants. The study started on 2006-07-11. Estimated completion is 2017-02-27.
What interventions are being tested in trial NCT00365105?
The interventions under investigation include: Vitamin D (DIETARY_SUPPLEMENT), zoledronic acid (DRUG), Calcium (DIETARY_SUPPLEMENT), Sm-153 (DRUG), Sr-89 (RADIATION).
Who is sponsoring clinical trial NCT00365105?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.